

AndrÃ© Baruchel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1170473/publications.pdf>

Version: 2024-02-01

80
papers

5,634
citations

394421

19
h-index

102487

66
g-index

80
all docs

80
docs citations

80
times ranked

8190
citing authors

#	ARTICLE	IF	CITATIONS
1	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 439-448.	27.0	3,680
2	Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials. <i>Journal of Clinical Oncology</i> , 2003, 21, 774-780.	1.6	552
3	Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 289-300.	1.4	97
4	Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. <i>Blood</i> , 2019, 134, 1351-1355.	1.4	89
5	Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?. <i>Blood</i> , 2018, 132, 351-361.	1.4	82
6	Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 538-548.	2.0	81
7	Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. <i>European Journal of Cancer</i> , 2014, 50, 3206-3211.	2.8	79
8	Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 3383-3393.	7.2	77
9	Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 895-895.	1.4	70
10	Ovarian reserve after treatment with alkylating agents during childhood. <i>Human Reproduction</i> , 2015, 30, 1437-1446.	0.9	67
11	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1710-1718.	10.7	65
12	Cohort Profile: The French Childhood Cancer Survivor Study For Leukaemia (LEA Cohort). <i>International Journal of Epidemiology</i> , 2015, 44, 49-57.	1.9	60
13	The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 348-357.	7.2	44
14	Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group. <i>HemaSphere</i> , 2018, 2, e31.	2.7	40
15	Eosinophilic pneumonias in children: A review of the epidemiology, diagnosis, and treatment. <i>Pediatric Pulmonology</i> , 2016, 51, 203-216.	2.0	31
16	Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. <i>Blood Advances</i> , 2021, 5, 2901-2908.	5.2	29
17	B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL. <i>Frontiers in Oncology</i> , 2019, 9, 1374.	2.8	28
18	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. <i>Blood</i> , 2022, 139, 1785-1793.	1.4	28

#	ARTICLE	IF	CITATIONS
19	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. <i>Leukemia</i> , 2022, 36, 1525-1532.	7.2	27
20	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
21	Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program. <i>Haematologica</i> , 2015, 100, e186-e189.	3.5	19
22	Maintenance Therapy With Interleukin-2 for Childhood AML. <i>HemaSphere</i> , 2018, 2, e159.	2.7	18
23	COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE). <i>Bulletin Du Cancer</i> , 2020, 107, 629-632.	1.6	18
24	Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 637951.	2.8	17
25	Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood lineage acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28112.	1.5	16
26	Employment in French young adult survivors of childhood leukemia: an LEA study (for Leucemies de Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 2016, 10, 1058-1066.	2.9	15
27	Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22 -positive B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 190, e53-e56.	2.5	15
28	Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10001-10001.	1.6	15
29	Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 425-427.	0.8	14
30	Hypoxia favors chemoresistance in T-ALL through an HIF1 α -mediated mTORC1 inhibition loop. <i>Blood Advances</i> , 2021, 5, 513-526.	5.2	14
31	Germline RUNX1 Intragenic Deletion: Implications for Accurate Diagnosis of FPD/AML. <i>HemaSphere</i> , 2019, 3, e203.	2.7	13
32	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 1981-1988.	5.2	12
33	Cranial polyneuropathy as the first manifestation of a severe COVID-19 in a child. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28707.	1.5	12
34	Therapeutic potential of ruxolitinib and ponatinib in patients with $\text{t}(11q23)\text{p15.5}$ -rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 2763-2767.	3.5	12
35	Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel. <i>Blood</i> , 2018, 132, 1551-1551.	1.4	12
36	The effect of age in patients with acquired aplastic anaemia treated with immunosuppressive therapy: comparison of Adolescents and Young Adults with children and older adults. <i>British Journal of Haematology</i> , 2018, 183, 766-774.	2.5	11

#	ARTICLE	IF	CITATIONS
37	Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27431.	1.5	11
38	Infant Acute Myeloid Leukemia: A Unique Clinical and Biological Entity. <i>Cancers</i> , 2021, 13, 777.	3.7	11
39	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. <i>Journal of Hematology and Oncology</i> , 2021, 14, 74.	17.0	10
40	Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT). <i>Blood</i> , 2012, 120, 3561-3561.	1.4	10
41	Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins. <i>Blood Cancer Journal</i> , 2022, 12, 14.	6.2	10
42	Evaluation of a New Device for Simplifying and Standardizing Stool Sample Preparation for Viral Molecular Testing with Limited Hands-On Time. <i>Journal of Clinical Microbiology</i> , 2016, 54, 928-933.	3.9	9
43	Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience. <i>Blood</i> , 2019, 134, 3876-3876.	1.4	9
44	Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1878-1882.	7.2	8
45	<i>KZF1</i> alterations predict poor prognosis in adult and pediatric T-ALL. <i>Blood</i> , 2021, 137, 1690-1694.	1.4	8
46	Adolescence and Socioeconomic Factors: Key Factors in the Long-Term Impact of Leukemia on Scholastic Performance—A LEA Study. <i>Journal of Pediatrics</i> , 2019, 205, 168-175.e2.	1.8	7
47	Considerations for tisagenlecleucel dosing rationale. <i>Journal of Clinical Oncology</i> , 2018, 36, e15056-e15056.	1.6	7
48	Isavuconazole Treatment for Invasive Fungal Infections in Pediatric Patients. <i>Pharmaceuticals</i> , 2022, 15, 375.	3.8	7
49	Relevance of a One-Year Maintenance Therapy with Interleukin-2 in the Treatment of Childhood Acute Myeloid Leukemia: Results from the French Multicenter, Phase III, Randomized Controlled Sfce Trial, ELAM02. <i>Blood</i> , 2014, 124, 378-378.	1.4	5
50	Updated Clinical Activity of Grasp Versus Native L-Asparaginase in Combination with Cooprrall Regimen in Phase 3 Randomized Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517). <i>Blood</i> , 2015, 126, 3723-3723.	1.4	5
51	Excellent Prognosis of Children with ETV6-RUNX1 Positive (+) Acute Lymphoblastic Leukemia (ALL) in the FRALLE 2000 Protocol. <i>Blood</i> , 2009, 114, 1628-1628.	1.4	5
52	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. <i>Modern Pathology</i> , 2022, 35, 1227-1235.	5.5	5
53	Genetic diversity of the human adenovirus species C DNA polymerase. <i>Antiviral Research</i> , 2018, 156, 1-9.	4.1	3
54	The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study): Pronostic Consideration. <i>Blood</i> , 2014, 124, 521-521.	1.4	3

#	ARTICLE	IF	CITATIONS
55	ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 42-42.	1.4	3
56	Bone Mineral Density Evolution and Its Determinants in Long-term Survivors of Childhood Acute Leukemia. <i>HemaSphere</i> , 2021, 5, e518.	2.7	2
57	Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols. <i>Leukemia</i> , 2021, , .	7.2	2
58	Switch to Subsequent Line of Treatment in Children and Adolescents with Chronic Myeloid Leukemia (CML) Treated with Imatinib: Experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped Study). <i>Blood</i> , 2015, 126, 1576-1576.	1.4	2
59	Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	1
60	Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study. <i>Blood</i> , 2019, 134, 5130-5130.	1.4	1
61	Assessment Of Minimal Residual Disease In Acute Myeloblastic Leukemia In Multiparameter Flow Cytometry. <i>Blood</i> , 2013, 122, 2613-2613.	1.4	1
62	Imatinib Has a Negative Impact On Growth In Children With Previously Untreated Chronic Myeloid Leukaemia (CML) In Early Chronic Phase (CP): Results Of The French National Study. <i>Blood</i> , 2013, 122, 4001-4001.	1.4	1
63	Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of GraspA in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517). <i>Blood</i> , 2015, 126, 3734-3734.	1.4	1
64	Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers. <i>Blood</i> , 2016, 128, 5190-5190.	1.4	1
65	Prognostic Discrimination of Children and Adolescents with Chronic Myeloid Leukemia Based on the EUTOS Long Term Survival (ELTS) Score. <i>Blood</i> , 2016, 128, 626-626.	1.4	1
66	The miRNA-193 Family Is a Potent Tumor-Suppressor and a Biomarker for Poor Prognosis in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1534-1534.	1.4	1
67	Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). <i>Journal of Cancer Research and Clinical Oncology</i> . 2022, , 1.	2.5	1
68	Two Decades of Progresses in Adolescents with Acute Lymphoblastic Leukemia (ALL) Treated in the FRALLE Protocols: Adolescence Is No More a Bad Prognostic Feature If an Intensive Chemotherapy Is Applied.. <i>Blood</i> , 2006, 108, 1852-1852.	1.4	0
69	Early Development of Immunity to CMV Following Hematopoietic-Stem Cell Transplantation Is Associated with Graft-Versus Leukaemia Effect. <i>Blood</i> , 2012, 120, 4214-4214.	1.4	0
70	Daunorubicin or Not During the Induction Treatment of Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): The Randomized Fralle 2000-A Protocol. <i>Blood</i> , 2012, 120, 135-135.	1.4	0
71	Risk Factors For Cerebral Vasculopathy In a Sickle Cell Disease Newborn Cohort. <i>Blood</i> , 2013, 122, 4685-4685.	1.4	0
72	New Design Of Human T-ALL Transplantation In NSG Mice Uncovers The Major Role Of CD31/PECAM1 In The Central Nervous System Infiltration. <i>Blood</i> , 2013, 122, 1436-1436.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Modeling Growth Of Pediatric T-ALL In Vivo and In Vitro: Clinical Meaning and Activation Of The NFkB Pathway. Blood, 2013, 122, 2571-2571.	1.4	0
74	Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T-Cell Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3723-3723.	1.4	0
75	DNA Methylation Profiling of Pediatric AML Reveals That Hypomethylation of MN1 Is Characteristic of Inv(16) AML and a Driver of MN1 Overexpression. Blood, 2014, 124, 867-867.	1.4	0
76	Bromodomain Inhibition By OTX015 Regulates c-MYC and HEXIM1 in a Panel of Human Acute Leukemia Cell Lines. Blood, 2014, 124, 5957-5957.	1.4	0
77	The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia. Blood, 2015, 126, 1244-1244.	1.4	0
78	Acceptability of the Fertility Preservation Program and Evaluation of the Gonadal Function in Children after Allogeneic Stem Cell Transplantation. Blood, 2015, 126, 4357-4357.	1.4	0
79	Impact of Two Different Types of Rabbit ATG on Immune Reconstitution and Overall Results after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Children. Blood, 2020, 136, 24-25.	1.4	0
80	JMML Fetal Identity Results Either from Retention of a Physiologic Signature or Aberrant Activation of Master Oncofetal Regulators. Blood, 2020, 136, 4-5.	1.4	0